

Suzanne K Vosburg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3254837/publications.pdf>

Version: 2024-02-01

12
papers

285
citations

1307594

7
h-index

1199594

12
g-index

13
all docs

13
docs citations

13
times ranked

318
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterizing the Experience of Tapentadol Nonmedical Use: Mixed Methods Study. JMIR Formative Research, 2022, 6, e16996.	1.4	2
2	Prescription Stimulant Nonmedical Use Among Adolescents Evaluated for Substance Use Disorder Treatment (CHATâ„†). Journal of Attention Disorders, 2021, 25, 1859-1870.	2.6	8
3	Characterizing prescription stimulant nonmedical use (NMU) among adults recruited from Reddit. Addictive Behaviors Reports, 2021, 14, 100376.	1.9	6
4	Evaluation of Abuse and Route of Administration of Extended-Release Tapentadol Among Treatment-Seeking Individuals, as Captured by the Addiction Severity Indexâ€™ Multimedia Version (ASI-MV). Pain Medicine, 2020, 21, 1891-1901.	1.9	10
5	Characterizing Pathways of Non-oral Prescription Stimulant Non-medical Use Among Adults Recruited From Reddit. Frontiers in Psychiatry, 2020, 11, 631792.	2.6	12
6	Assessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System. Journal of Pain, 2018, 19, 439-453.	1.4	39
7	Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addictionâ€™Related Surveillance (RADARS) System Web Monitoring Program. Pharmacoepidemiology and Drug Safety, 2017, 26, 1044-1052.	1.9	12
8	The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers. Addiction Biology, 2016, 21, 895-903.	2.6	85
9	Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphineâ€™maintained heroin users. Addiction Biology, 2015, 20, 784-798.	2.6	28
10	A comparison among tapentadol tamperâ€™resistant formulations (<sc>TRF</sc>) and <sc>OC</sc><sc>C</sc>ontin^{Â®} (nonâ€™<sc>TRF</sc>) in prescription opioid abusers. Addiction, 2013, 108, 1095-1106.	3.3	38
11	Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug and Alcohol Dependence, 2012, 126, 206-215.	3.2	42
12	Evaluation of the reinforcing and subjective effects of heroin in combination with dextromethorphan and quinidine. Journal of Opioid Management, 2011, 7, 451-461.	0.5	3